Mirikizumab treatment is safe and efficacious for ulcerative colitis up to 152 weeks in those with and without previous biologic therapy failure. Mirikizumab treatment for 152 weeks is associated with ...

Learn how prebiotics, or foods with compounds that support a healthy balance of gut bacteria (microbiome), may benefit people ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...

A patient at the University of Chicago became the first person to receive a recently FDA-approved treatment for moderate to severe ulcerative colitis, according to a Sept. 17 news release by the ...

Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek ...

A new study published in the journal of Inflammatory Bowel Disease shows low mortality and tolerable morbidity after total ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...

Researchers at the University of Michigan Health Rogel Cancer Center discovered a new mechanism for eliminating one of the main side effects of immunotherapy treatment: colitis. Immunotherapy is used ...

Fulminant colitis is a rare but severe form of colitis that can be life threatening. It affects the entire lining of the colon, causing severe inflammation and potentially serious complications. In ...